Everything below concerns Reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
A dosage of two to six 100 μg/day transdermal estradiol patches can achieve mean levels of estradiol in the area of 200 to 400 pg/mL and can be used as a form of high-dose estrogen therapy, for instance to suppress testosterone levels in the treatment of prostate cancer in men and in feminizing hormone therapy for transgender women. High-dose transdermal estradiol patches have also been studied in the treatment of postpartum depression and postpartum psychosis; in one such study, 200, 400, and 800 μg/day estradiol in the form of transdermal patches resulted in estradiol levels of 286 pg/mL, 675 pg/mL, and 1032 pg/mL, respectively. In another study, estradiol levels with 800 μg/day estradiol in the form of transdermal patches (Estraderm TTS) resulted in estradiol levels of 690 to 815 pg/mL. However, there is erratic absorption and considerable variation in estradiol levels using high-dose estradiol patches both between and within individuals, with one study finding that estradiol levels ranged from 70 pg/mL to 1,045 pg/mL (mean 460.7 pg/mL) with six 100 μg/day estradiol patches. The Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) study is a randomized controlled trial of high-dose transdermal estradiol patches versus gonadotropin-releasing hormone agonist monotherapy in the treatment of prostate cancer in approximately 2,200 men. It is specifically comparing three to four 100 μg/day estradiol patches (FemSeven) against goserelin implants. The study was started in March 2006 and is estimated for completion in August 2021.
One arm lying west of the body, 23 feet long; one stump of arm about 4 feet long; three arms lying south of body and from appearance attached to same (although I did not dig quite to body, as it laid well down in the sand and I was very tired), longest one measured over 23 feet, the other arms were three to five feet shorter. In the first days of December 1896, Dr. George Grant, owner of a hotel at South Beach on Anastasia Island, wrote a short article describing the carcass, which was published in the Pennsylvania Grit of Williamsport on December 13. The article was accompanied by a picture of the "sea monster" depicting a tentacled creature with a tail. This was drawn by the draughtsman of the newspaper based on Grant's description, and not an eyewitness. Grant's description was as follows:
Mural Painting: cool, dry, glue, tempera, sgraffito Easel Painting and Altars: canvas, board, altarpiece Sculptural and Ornamental Materials: stone, mortar, stucco, bronze, terracotta, wood Golden, polychrome, furniture and expertizing Archaeological and ethnographic materials: flooring, tiles, ceramic tiles, glass, archaeological remains, tapestry, vestment, robes Graphic and Documentary: drawing, scroll, prints, book, photograph, manuscript The intervention Area of Architectural Heritage comprises:
A more recent preparation method pioneered by the Royal Ontario Museum removes all bones for a complete skeleton while also producing a round skin without bill or legs (called a ROM, though if one set of wing and leg bones remain with the skin the preparation is called a shmoo in North America). Alternatively, the entire bird (or any soft parts associated with preparations described above) may be preserved in alcohol. For any of these methods, several supplemental preparations may be made. For example, a wing may be removed and preserved separately as a spread wing for better study of flight feathers; a tissue sample may be removed and frozen for molecular analyses; or a recording of the bird's song before collection may be archived. Neither molecular samples nor sound recordings require a bird to be collected (killed). Finally, if the bird is too rotten for the skin and feathers to be preserved, as is the case with some salvaged specimens, the skeleton alone may be preserved. Dried tissue is removed from skeletons by using dermestid beetle larvae (genus Dermestes). Whereas in the past arsenic was routinely added to skins to protect them from destruction by insects, specimens prepared today are generally protected by an initial freezing period to kill insects and their eggs followed by keeping them in high-quality museum cases in a climate-controlled room. Each specimen has data associated with it, and the amount of data available is usually directly correlated with the specimen's scientific value.
Unlike other Dexcom models, Stelo is available over the counter and does not require a prescription. As of December 1, 2025, both the Dexcom G7 15-Day; G7 and Stelo are available in the U.S. market, only the G7 and Stelo are available internationally.
Sources: en.wikipedia.org
A large number of illnesses and diseases are caused by mutations in alleles of the genes that regulate the production of actin or of its associated proteins. The production of actin is also key to the process of infection by some pathogenic microorganisms. Mutations in the different genes that regulate actin production in humans can cause muscular diseases, variations in the size and function of the heart, as well as deafness. The make-up of the cytoskeleton is also related to the pathogenicity of intracellular bacteria and viruses, particularly in the processes related to evading the actions of the immune system.
However, even after the initial recruitment phase, when head-shaving is no longer required, many soldiers maintain a completely or partially shaven hairstyle (such as a "high and tight", "flattop" or "buzz cut") for personal convenience or neatness. Head-shaving is not required and is often not permitted for women in military service, although they must have their hair cut or tied to regulation length. For example, the shortest hair a female soldier can have in the U.S. Army is 1/4 inch from the scalp.
== Mechanisms == Chronic elevation of blood glucose level leads to damage of blood vessels called angiopathy. The endothelial cells lining the blood vessels take in more glucose than normal, since they do not depend on insulin. They then form more surface glycoproteins than normal, and cause the basement membrane to grow thicker and weaker. The resulting problems are grouped under "microvascular disease" due to damage to small blood vessels and "macrovascular disease" due to damage to the arteries. Studies show that DM1 and DM2 cause a change in balancing of metabolites such as carbohydrates, blood coagulation factors, and lipids, and subsequently bring about complications like microvascular and cardiovascular complications. The role of metalloproteases and inhibitors in diabetic renal disease is unclear. Numerous researches have found inconsistent results about the role of vitamins in diabetic risk and complications.
The "city symphony" sub film genre consisted of avant-garde films during the 1920s and 1930s. These films were particularly influenced by modern art, namely Cubism, Constructivism, and Impressionism. According to art historian and author Scott MacDonald, city symphony films can be described as, "An intersection between documentary and avant-garde film: an avant-doc"; however, A.L. Rees suggests regarding them as avant-garde films. Early titles produced within this genre include: Manhatta (New York; dir. Paul Strand, 1921); Rien que les heures/Nothing But The Hours (France; dir. Alberto Cavalcanti, 1926); Twenty Four Dollar Island (dir. Robert J. Flaherty, 1927); Moscow (dir. Mikhail Kaufman, 1927); Études sur Paris (dir. André Sauvage, 1928); The Bridge (1928) and Rain (1929), both by Joris Ivens; São Paulo, Sinfonia da Metrópole (dir. Adalberto Kemeny, 1929), Berlin: Symphony of a Metropolis (dir. Walter Ruttmann, 1927); Man with a Movie Camera (dir. Dziga Vertov, 1929); Douro, Faina Fluvial (dir. Manoel de Oliveira, 1931); and Rhapsody in Two Languages (dir. Gordon Sparling, 1934). A city symphony film, as the name suggests, is most often based around a major metropolitan city area and seeks to capture the life, events and activities of the city. It can use abstract cinematography (Walter Ruttman's Berlin) or may use Soviet montage theory (Dziga Vertov's Man with a Movie Camera). Most importantly, a city symphony film is a form of cinepoetry, shot and edited in the style of a "symphony".
=== Corporate management === Chipotle's team includes a residing corporate office of managers and its board of directors. Members of both teams are appointed to serve on committees: audit, compensation, and nominating and corporate governance. By late 2016, the top management team consisted of the chief executive officer, Steve Ells; the chief financial officer, Jack R. Hartung; the chief marketing and development officer, Mark Crumpacker. At that time, the board of directors consists of: Ells, Patrick Flynn, Albert Baldocchi, Neil Flanzraich, Darlene Friedman, Stephen Gillet, Kimbal Musk and John Charlesworth. On March 14, 2018, it was reported that Mark Crumpacker, who had previously been charged in a 2016 cocaine ring indictment, would be leaving the company. Ells was chairman of the company, and was chief executive officer until November 2017. He had a 1.25% stake in the company in 2010. The labor-market research firm Glassdoor reported that Ells earned $29 million in 2014, versus a median of $19,000 for Chipotle's workers, making the CEO-to-worker pay ratio 1522:1. On February 13, 2018, Chipotle announced that Taco Bell CEO Brian Niccol would replace Ells as CEO starting on March 5 while Ells would retain his chairman position. On March 6, 2020, Ells resigned as chairman and left the board of directors, breaking his final ties to the company. At the same time, Niccol was appointed chairman, and the size of the board was reduced from ten to seven directors. On August 13, 2024, Starbucks announced it was hiring Niccol as its next CEO.
Sources: en.wikipedia.org
2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine or by names such as Nexus or Erox, is a psychedelic drug of the phenethylamine and 2C families. The drug is used as a recreational drug and is usually taken orally. 2C-B produces hallucinogenic, mild stimulant, and mild entactogenic-like effects. Its hallucinogenic effects at typical doses are milder than those of other psychedelics like LSD or psilocybin. The drug acts as a potent partial agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A receptor. It produces psychedelic-like effects in animals. Numerous analogues and derivatives of 2C-B are known, such as DOB, 2C-B-FLY, and 25B-NBOMe among others. 2C-B was developed by Alexander Shulgin in 1974 and was described by him in the scientific literature in 1975. The drug emerged as a novel recreational designer drug and MDMA (ecstasy) substitute in the mid-1980s. Subsequently, it became a controlled substance in the United States in the mid-1990s. 2C-B was one of the first 2C psychedelics to be described. It is the most popular and well-known of the 2C psychedelics and is one of the most widely used designer drugs.
== Chemistry == Radium only exhibits the oxidation state of +2 in solution. It forms the colorless Ra2+ cation in aqueous solution, which is highly basic and does not form complexes readily. Most radium compounds are therefore simple ionic compounds, though participation from the 6s and 6p electrons (in addition to the valence 7s electrons) is expected due to relativistic effects and would enhance the covalent character of radium compounds such as RaF2 and RaAt2. For this reason, the standard electrode potential for the half-reaction Ra2+ (aq) + 2e- → Ra (s) is −2.916 V, even slightly lower than the value −2.92 V for barium, whereas the values had previously smoothly increased down the group (Ca: −2.84 V; Sr: −2.89 V; Ba: −2.92 V). The values for barium and radium are almost exactly the same as those of the heavier alkali metals potassium, rubidium, and caesium.
== Testing == The presence of stimulants in the body may be tested by a variety of procedures. Serum and urine are the common sources of testing material although saliva is sometimes used. Commonly used tests include chromatography, immunologic assay, and mass spectrometry.
=== Availability === The "reference" version of BLOSUM is found in the NCBI toolkits. Both the older (deprecated) NCBI C Toolkit and the current NCBI C++ Toolkit provide the BLOSUM45, BLOSUM50, BLOSUM62, BLOSUM80, and BLOSUM90 matrices. Both also offer APIs for making use of the matrices. The original source code for calculating BLOSUM is also found on the NCBI website, at https://ftp.ncbi.nih.gov/repository/blocks/unix/blosum/. This archive "blosum.tar.Z" represents the original miscalculated version with improved search performance from 1992. The archive also contains pre-calculated BLOSUM outputs at the following similarity levels: "-2" (blosumn), 30, 40, 45, 50, 55, 60, 62, 65, 70, 75, 80, 85, 90, 95, and 100.
Afropop Worldwide's public radio program on Zulu Music, "The Zulu Factor" People of Africa, Zulu marriage explained An article on Piet Retief, including his interactions with Dingane History section of the official page for the Zululand region Archived 26 September 2008 at the Wayback Machine Human Rights Watch report on KwaZulu, just before the 1994 elections – This includes detailed, well-referenced, sections on recent Zulu history.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.